Journal of Molecular Medicine and Therapy

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.


Canagliflozin is used lengthwise with diet and isometrics, and occasionally with other medications, to lower plasma sugar heights in individuals with type 2 diabetes (circumstance in which blood sugar is too great because the form does not harvest or use insulin generally). Canagliflozin is also used to decrease the risk of whack, heart attack, or death in people who have type 2  diabetes beside with heart and blood vessel infection. Canagliflozin is also used to decrease the risk of end-stage kidney disease, fading of kidney function, demanding to be hospitalized for emotion failure, and cardiovascular death in individuals who have type 2 diabetes along with plain kidney disease. Canagliflozin is in a class of medicines called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It drops blood sugar by producing the kidneys to get cleared of more glucose in the urine. Canagliflozin is not used to indulgence type 1 diabetes (circumstance in which the body does not harvest insulin)

High Impact List of Articles
Conference Proceedings

Relevant Topics in Genetics & Molecular Biology